Neuromodulation in Heart Failure
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Early experience with baroreflex activation therapy from a vascular surgery perspective.
Chow C, Montoya C, Sussman M, Kenel-Pierre S, Velazquez O, Grazette L J Vasc Surg Cases Innov Tech. 2025; 10(6):101464.
PMID: 40027264 PMC: 11868725. DOI: 10.1016/j.jvscit.2024.101464.
References
1.
Duncker D, Bauersachs J
. Current and future use of neuromodulation in heart failure. Eur Heart J Suppl. 2022; 24(Suppl E):E28-E34.
PMC: 9385118.
DOI: 10.1093/eurheartjsupp/suac031.
View
2.
Butler J, Packer M, Filippatos G, Ferreira J, Zeller C, Schnee J
. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2021; 43(5):416-426.
PMC: 8825259.
DOI: 10.1093/eurheartj/ehab798.
View
3.
Ferreira J, Duarte K, Graves T, Zile M, Abraham W, Weaver F
. Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. J Am Coll Cardiol. 2016; 68(24):2690-2707.
DOI: 10.1016/j.jacc.2016.09.936.
View
4.
Dusi V, Angelini F, Zile M, De Ferrari G
. Neuromodulation devices for heart failure. Eur Heart J Suppl. 2022; 24(Suppl E):E12-E27.
PMC: 9385122.
DOI: 10.1093/eurheartjsupp/suac036.
View
5.
Gronda E, Dusi V, DElia E, Iacoviello M, Benvenuto E, Vanoli E
. Sympathetic activation in heart failure. Eur Heart J Suppl. 2022; 24(Suppl E):E4-E11.
PMC: 9385124.
DOI: 10.1093/eurheartjsupp/suac030.
View